Botswana

Reimbursed Care Access

Botswana’s formal pharmaceutical framework provides for the medical use of conventional anaesthetics including ketamine (listed on the national essential medicines list), but there is no established national medical program, reimbursement pathway, or routine licensed use for classical psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X, ibogaine) outside of tightly regulated clinical research. Esketamine (Spravato) does not appear on Botswana’s published essential medicines listing and there is no public record of a national registration / reimbursement pathway for esketamine as of the sources checked; most classical psychedelics remain controlled internationally under UN conventions and therefore are treated as controlled substances domestically unless a specific local regulatory exemption or clinical trial authorization exists. [https://www.scribd.com/document/570053299/Botswana-Essential-Medicines-List-3rd-Edition-Electronic-Version-June-2016|Botswana Essential Medicines List 2016] [https://en.wikipedia.org/wiki/Convention_on_Psychotropic_Substances|Convention on Psychotropic Substances (UN)].